Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ERBB3 act mut |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor HER3 Inhibitor Pertuzumab Trastuzumab |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07193394 | Phase II | Trastuzumab + Tucatinib | Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer (H3RAKLES) | Recruiting | FRA | 0 |
| NCT02673398 | Phase II | Neratinib | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Completed | USA | 0 |